Date | Price Target | Rating | Analyst |
---|---|---|---|
9/10/2024 | $3.00 | Buy | Lake Street |
3/29/2023 | $2.25 | Neutral | UBS |
11/29/2022 | $4.50 | Outperform | Oppenheimer |
10/4/2022 | $9.50 | Buy | B. Riley Securities |
12/17/2021 | $7.00 | Neutral | UBS |
SC 13D/A - Butterfly Network, Inc. (0001804176) (Subject)
SC 13D/A - Butterfly Network, Inc. (0001804176) (Subject)
SC 13G/A - Butterfly Network, Inc. (0001804176) (Subject)
4 - Butterfly Network, Inc. (0001804176) (Issuer)
4 - Butterfly Network, Inc. (0001804176) (Issuer)
4 - Butterfly Network, Inc. (0001804176) (Issuer)
Reports Record Quarterly Revenue Raises Full Year Adjusted EBITDA Guidance Delivered record quarterly Revenue of $21.5 million in Q2, representing 16% YoY growth Reduced Q2 Net Loss by 45% and Net Cash Used in Operations by 62% Successfully launched medical school Campus Essentials program Launched iQ3 in Canada and expanded into new markets in Southeast Asia Filed for revocation of the RoHS handheld piezoelectric crystal ultrasound exemptions Butterfly Network, Inc. (NYSE:BFLY) ("Butterfly" or the "Company"), a digital health company transforming care with portable, semiconductor-based ultrasound technology and intuitive software, today announced financial results for t
07/18/2024 Butterfly Network, Inc. (NYSE:BFLY) ("Butterfly"), a digital health company transforming care with portable, semiconductor-based ultrasound technology and intuitive software, announced that it will report second quarter 2024 financial results on August 1, 2024, after the market closes. Joseph DeVivo, President, Chief Executive Officer and Chairman of the Board, and Heather Getz, Executive Vice President and Chief Financial and Operations Officer, will host a conference call and webcast at 5:00 pm ET on August 1, 2024, to discuss second quarter 2024 financial results and operational progress. The conference call will be broadcast live in listen-only mode via a webcast on But
Achieves 14% Revenue Growth - Exceeding Expectations Raises Full Year Guidance Delivered record first quarter Revenue of $17.7 million Reduced Net Loss by 35% and Net Cash Used in Operations by 52% Successfully launched next generation device Butterfly iQ3™ and training app ScanLab™ Received European Union Medical Device Regulation (EU MDR) certification Butterfly Network, Inc. (NYSE:BFLY) ("Butterfly" or the "Company"), a digital health company transforming care with handheld, whole-body ultrasound and intuitive software, today announced financial results for the first quarter ended March 31, 2024, and provided a business update. Joseph DeVivo, Butterfly's Chairman and CEO
4 - Butterfly Network, Inc. (0001804176) (Issuer)
4 - Butterfly Network, Inc. (0001804176) (Issuer)
4 - Butterfly Network, Inc. (0001804176) (Issuer)
Lake Street initiated coverage of Butterfly Network with a rating of Buy and set a new price target of $3.00
UBS initiated coverage of Butterfly Network with a rating of Neutral and set a new price target of $2.25
Oppenheimer initiated coverage of Butterfly Network with a rating of Outperform and set a new price target of $4.50
Seasoned Healthcare Leader to Drive Growth Strategy and Amplify Continued Commercial Momentum Butterfly Network, Inc. (NYSE:BFLY), a digital health company transforming care with portable, semiconductor-based ultrasound technology and intuitive software, announced the appointment of Steve Cashman as Chief Business Officer (CBO), effective today. Cashman joins Butterfly at an exciting juncture, following the Company's successful launch of its third-generation Butterfly iQ3 and historic revenue performance in the first half of 2024. Cashman will join Butterfly's Executive Management Team, overseeing the Company's global sales, marketing, product and corporate strategy. This press release f
SAN FRANCISCO, Aug. 20, 2024 /PRNewswire/ -- Avive Solutions, Inc., a manufacturer of innovative Automated External Defibrillators (AEDs) and software solutions to improve access to AEDs and response to cardiac arrest emergencies, is excited to announce the appointment of Katerina Miras as their Vice President of Marketing. A visionary marketing leader with extensive experience in medtech, Miras brings a wealth of expertise in creating memorable healthcare brands that accelerate commercial growth. "I am honored to join Avive's leadership team at such a transformative time for
Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of Heather Getz as a Class II director and chair of its audit committee effective March 26, 2024, to serve until the 2025 annual meeting of stockholders. With this appointment, Myomo has seven directors. Ms. Getz brings more than 25 years of corporate experience creating long-term value through financial, general management, and healthcare leadership. She has significant expertise in finance, reimbursement, investor relations, compliance, M&A and strategic plannin
144 - Butterfly Network, Inc. (0001804176) (Subject)
10-Q - Butterfly Network, Inc. (0001804176) (Filer)
8-K - Butterfly Network, Inc. (0001804176) (Filer)
URMC increased ultrasound charge capture by 116% following system-wide deployment of Butterfly Network devices and Compass™ workflow software. URMC's implementation results published on September 16, 2024 in the Journal of Clinical Imaging Science. Butterfly Network, Inc. ("Butterfly", "the Company") (NYSE:BFLY), a digital health company transforming care through the power of portable, semiconductor-based ultrasound technology and intuitive software, today published a case study highlighting the positive impact of University of Rochester Medical Center's (URMC) transformative, system-wide deployment of Butterfly's point-of-care ultrasound (POCUS) devices and enterprise ultrasound platf
Butterfly Network, Inc. ("Butterfly") (NYSE:BFLY), a digital health company transforming care through the power of portable, semiconductor-based ultrasound technology and intuitive software, today announced that Fierce Life Sciences and Fierce Healthcare have named Butterfly as one of 2024's Fierce 50 honorees. The Fierce 50 showcases 50 individuals and companies driving advancements in medicine, fostering innovation, and shaping the future of biopharma and healthcare. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240909393991/en/Butterfly Network named a 2024 Fierce 50 Honoree. (Graphic: Business Wire) Butterfly's inclusion in
September 12, 2024 Butterfly Network, Inc. (NYSE:BFLY) ("Butterfly"), a digital health company transforming care with handheld, whole-body ultrasound and intuitive software, today announced its participation in Lake Street Capital Markets' 8th Annual Best Ideas Growth Conference, taking place in New York City on September 12, 2024. Heather Getz, Chief Financial and Operations Officer at Butterfly Network, will represent Butterfly in one-on-one investor meetings at the conference. For more information or to schedule a meeting with Heather Getz at the conference, please contact your Lake Street representative. About Butterfly Network Founded by Dr. Jonathan Rothberg in 2011, Butterf
With iQ+ Bladder, Butterfly expands outside its core point-of-care ultrasound market to better serve the bladder scanning market with its proprietary Ultrasound-on-Chip™ technology.The bundled bladder solution includes an iQ+ Bladder probe, streamlined software, compact rolling cart, tablet and power splitter, paired with premium assembly.Butterfly Network, Inc. ("Butterfly", "the Company") (NYSE:BFLY), a digital health company transforming care through the power of portable, semiconductor-based ultrasound technology and intuitive software, today introduced its first specialty product, iQ+ Bladder™, now available for purchase in the United States. The bundled solution includes an iQ+ Bladder
Gainers Allarity Therapeutics (NASDAQ:ALLR) stock moved upwards by 106.6% to $2.83 during Thursday's pre-market session. The market value of their outstanding shares is at $5.5 million. Emergent BioSolutions (NYSE:EBS) shares moved upwards by 52.84% to $2.95. The market value of their outstanding shares is at $154.5 million. As per the press release, Q1 earnings came out yesterday. Aptevo Therapeutics (NASDAQ:APVO) stock rose 35.41% to $1.3. The company's market cap stands at $4.6 million. Context Therapeutics (NASDAQ:CNTX) stock rose 34.55% to $1.83. The company's market cap stands at $29.2 million. Skye Bioscience (NASDAQ:SKYE) stock increased by 25.09% to $16.0. The company's market